SCHEMBL27166334

SCHEMBL27166334

C#CCOCCCOC(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
LMNA P02545 2/20 0.38
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
CHRNB2 P17787 2/20 0.36
CHRNA4 P43681 2/20 0.36
HTR1A P08908 1/20 0.36
CYP2C19 P33261 1/20 0.36
CHRNA7 P36544 1/20 0.36
ALOX15 P16050 1/20 0.33
NPC1 O15118 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32
SLC1A1 P43005 1/20 0.32
CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28715308 0.96 TSHR (0.52) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL28715324 0.96 TSHR (0.55) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL13737752 0.88 TSHR (0.48) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL28515744 0.86 TSHR (0.47) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL26924598 0.86 TSHR (0.47) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL29239038 0.80 TSHR (0.40) TSHRLMNACA12CA1CA2
SCHEMBL7254965 0.78 TSHR (0.58) TSHR
SCHEMBL2745809 0.78 LMNA (0.52) TSHRLMNACHRM2CHRM4CHRM5
SCHEMBL6684107 0.77
SCHEMBL2359427 0.76 TSHR (0.55) TSHRLMNACHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 EP disclosed
CN-116783205-A Compounds for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway 尼坎治疗公司 2023-09-19 CN disclosed